Alexander Everhart1,2, Nihar R Desai3, Bryan Dowd1, Jeph Herrin3, Lucas Higuera1,4, Molly Moore Jeffery5, Anupam B Jena6,7,8, Joseph S Ross3, Nilay D Shah5, Laura Barrie Smith9, Pinar Karaca-Mandic1,8. 1. University of Minnesota, Minneapolis, Minnesota, USA. 2. OptumLabs Visiting Fellow, Eden Prairie, Minnesota, USA. 3. Yale School of Medicine, Charlottesville, Virginia, USA. 4. Medtronic Plc, Mounds View, Minnesota, USA. 5. Mayo Clinic, Rochester, Minnesota, USA. 6. Harvard Medical School, Boston, Massachusetts, USA. 7. Massachusetts General Hospital, Boston, Massachusetts, USA. 8. National Bureau of Economic Research, Cambridge, Massachusetts, USA. 9. Urban Institute, Washington, District of Columbia, USA.
Abstract
OBJECTIVE: To describe physicians' variation in de-adopting concurrent statin and fibrate therapy for type 2 diabetic patients following a reversal in clinical evidence. DATA SOURCES: We analyzed 2007-2015 claims data from OptumLabs® Data Warehouse, a longitudinal, real-world data asset with de-identified administrative claims and electronic health record data. STUDY DESIGN: We modeled fibrate use among Medicare Advantage and commercially insured type 2 diabetic statin users before and after the publication of the ACCORD lipid trial, which found statins and fibrates were no more effective than statins alone in reducing cardiovascular events among type 2 diabetic patients. We modeled fibrate use trends with physician random effects and physician characteristics such as age and specialty. DATA EXTRACTION: We identified patient-year-quarters with one year of continuous insurance enrollment, type 2 diabetes diagnoses, and fibrate use. We designated the physician most responsible for patients' diabetes care based on evaluation and management visits and prescriptions of glucose-lowering drugs. PRINCIPAL FINDINGS: Fibrate use increased by 0.12 percentage points per quarter among commercial patients (95% CI, 0.10 to 0.14) and 0.17 percentage points per quarter among Medicare Advantage patients (95% CI, 0.13 to 0.20) before the trial and then decreased by 0.16 percentage points per quarter among commercial patients (95% CI, -0.18 to -0.15) and 0.05 percentage points per quarter among Medicare Advantage patients (95% CI, -0.06 to -0.03) after the trial. However, 45% of physicians treating commercial patients and 48% of physicians treating Medicare Advantage patients had positive trends in prescribing following the trial. Physicians' characteristics did not explain their variation (pseudo R2 = 0.000). CONCLUSION: On average, physicians decreased fibrate prescribing following the ACCORD lipid trial. However, many physicians increased prescribing following the trial. Observable physician characteristics did not explain variations in prescribing. Future research should examine whether physicians vary similarly in other de-adoption settings.
OBJECTIVE: To describe physicians' variation in de-adopting concurrent statin and fibrate therapy for type 2 diabetic patients following a reversal in clinical evidence. DATA SOURCES: We analyzed 2007-2015 claims data from OptumLabs® Data Warehouse, a longitudinal, real-world data asset with de-identified administrative claims and electronic health record data. STUDY DESIGN: We modeled fibrate use among Medicare Advantage and commercially insured type 2 diabetic statin users before and after the publication of the ACCORD lipid trial, which found statins and fibrates were no more effective than statins alone in reducing cardiovascular events among type 2 diabetic patients. We modeled fibrate use trends with physician random effects and physician characteristics such as age and specialty. DATA EXTRACTION: We identified patient-year-quarters with one year of continuous insurance enrollment, type 2 diabetes diagnoses, and fibrate use. We designated the physician most responsible for patients' diabetes care based on evaluation and management visits and prescriptions of glucose-lowering drugs. PRINCIPAL FINDINGS: Fibrate use increased by 0.12 percentage points per quarter among commercial patients (95% CI, 0.10 to 0.14) and 0.17 percentage points per quarter among Medicare Advantage patients (95% CI, 0.13 to 0.20) before the trial and then decreased by 0.16 percentage points per quarter among commercial patients (95% CI, -0.18 to -0.15) and 0.05 percentage points per quarter among Medicare Advantage patients (95% CI, -0.06 to -0.03) after the trial. However, 45% of physicians treating commercial patients and 48% of physicians treating Medicare Advantage patients had positive trends in prescribing following the trial. Physicians' characteristics did not explain their variation (pseudo R2 = 0.000). CONCLUSION: On average, physicians decreased fibrate prescribing following the ACCORD lipid trial. However, many physicians increased prescribing following the trial. Observable physician characteristics did not explain variations in prescribing. Future research should examine whether physicians vary similarly in other de-adoption settings.
Authors: Vinay Prasad; Andrae Vandross; Caitlin Toomey; Michael Cheung; Jason Rho; Steven Quinn; Satish Jacob Chacko; Durga Borkar; Victor Gall; Senthil Selvaraj; Nancy Ho; Adam Cifu Journal: Mayo Clin Proc Date: 2013-07-18 Impact factor: 7.616
Authors: Jeanette W Chung; Min-Woong Sohn; Ryan P Merkow; Elissa H Oh; Christina Minami; Bernard S Black; Karl Y Bilimoria Journal: Health Serv Res Date: 2013-10-11 Impact factor: 3.402
Authors: Alexander Everhart; Nihar R Desai; Bryan Dowd; Jeph Herrin; Lucas Higuera; Molly Moore Jeffery; Anupam B Jena; Joseph S Ross; Nilay D Shah; Laura Barrie Smith; Pinar Karaca-Mandic Journal: Health Serv Res Date: 2021-02-10 Impact factor: 3.734
Authors: Ashwini Sankar; Kristi M Swanson; Jiani Zhou; Anupam Bapu Jena; Joseph S Ross; Nilay D Shah; Pinar Karaca-Mandic Journal: JAMA Netw Open Date: 2021-12-01
Authors: Azita H Talasaz; Parham Sadeghipour; Maryam Aghakouchakzadeh; Isaac Dreyfus; Hessam Kakavand; Hamid Ariannejad; Aakriti Gupta; Mahesh V Madhavan; Benjamin W Van Tassell; David Jimenez; Manuel Monreal; Muthiah Vaduganathan; John Fanikos; Dave L Dixon; Gregory Piazza; Sahil A Parikh; Deepak L Bhatt; Gregory Y H Lip; Gregg W Stone; Harlan M Krumholz; Peter Libby; Samuel Z Goldhaber; Behnood Bikdeli Journal: J Am Coll Cardiol Date: 2021-10-19 Impact factor: 27.203
Authors: Alexander Everhart; Nihar R Desai; Bryan Dowd; Jeph Herrin; Lucas Higuera; Molly Moore Jeffery; Anupam B Jena; Joseph S Ross; Nilay D Shah; Laura Barrie Smith; Pinar Karaca-Mandic Journal: Health Serv Res Date: 2021-02-10 Impact factor: 3.734